AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2026
Feb 23, 2026
30604_dirs_2026-02-23_fc2ab739-5962-4eb0-9e08-c59cf2b1bcfc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2026-02-19
Reporting Person: Kumar Neil (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-19 | Common Stock | S | 18923 | $71.0347 | Disposed | 243581 | Direct |
| 2026-02-19 | Common Stock | S | 8528 | $72.0804 | Disposed | 235053 | Direct |
| 2026-02-19 | Common Stock | S | 602 | $72.801 | Disposed | 234451 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 675686 | Indirect |
| Common Stock | 4478447 | Indirect |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
F2: Represents the weighted average sale price of the shares sold from $70.61 to $71.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: Represents the weighted average sale price of the shares sold from $71.61 to $72.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4: Represents the weighted average sale price of the shares sold from $72.61 to $72.86 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.